| TYMP |
|---|
| Symbol | TYMP |
| Full Name | Thymidine Phosphorylase |
| Chromosome | 22q13.33 |
| NCBI Gene ID | [7290](https://www.ncbi.nlm.nih.gov/gene/7290) |
| OMIM | [131400](https://omim.org/entry/131400) |
| Ensembl | [ENSG00000012223](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000012223) |
| UniProt | [Q9H3K2](https://www.uniprot.org/uniprot/Q9H3K2) |
| Aliases | TP, PD-ECGF, ECGF |
TYMP encodes thymidine phosphorylase (TP), also known as platelet-derived endothelial cell growth factor (PD-ECGF). This enzyme catalyzes the reversible phosphorolysis of thymidine to thymine and 2-deoxyribose-1-phosphate, playing a crucial role in nucleoside metabolism and mitochondrial DNA (mtDNA) maintenance.
TYMP is essential for the proper balance of nucleotide pools required for mtDNA replication and repair. Loss of TYMP function leads to mitochondrial DNA depletion syndrome (MTDPS), specifically the form known as Mitochondrial Neurogastrointestinal Encephalomyopathy (MNGIE). This severe multisystem disorder is characterized by progressive external ophthalmoplegia (PEO), gastrointestinal dysmotility, leukoencephalopathy, and peripheral neuropathy.
¶ Enzyme Activity and Catalysis
Thymidine phosphorylase catalyzes the reversible reaction:
Thymidine + phosphate ⇌ Thymine + 2-deoxyribose-1-phosphate
This reaction is part of the pyrimidine salvage pathway, which recycles nucleosides from RNA and DNA degradation. TYMP:
- Has broad substrate specificity for pyrimidine nucleosides
- Uses inorganic phosphate as the phosphate donor
- Produces 2-deoxyribose-1-phosphate, which is further metabolized
- Functions in both catabolic and anabolic directions depending on cellular needs
¶ Role in Mitochondrial DNA Maintenance
TYMP's critical function in mtDNA maintenance is mediated through its role in nucleoside balance:
- Nucleotide pool regulation — TYMP helps maintain balanced pools of dNTPs for mtDNA synthesis
- Thymidine homeostasis — Prevents toxic accumulation of thymidine
- Mitochondrial dNTP synthesis — Contributes to the unique dNTP pool in mitochondria
- mtDNA replication — Adequate nucleotides are essential for replication
- mtDNA repair — Nucleotide availability affects repair capacity
flowchart TD
A["TYMP Enzyme<br/>Thymidine Phosphorylase"] --> B["Pyrimidine<br/>Salvage Pathway"]
B --> C["Nucleotide<br/>Pool Balance"]
C --> D["Mitochondrial dNTP<br/>Pool Regulation"]
D --> D1["mtDNA<br/>Replication"]
D --> D2["mtDNA<br/>Repair"]
D --> D3["mtDNA<br/>Maintenance"]
D1 --> E["Normal Mitochondrial<br/>Function"]
D2 --> E
D3 --> E
style A fill:#e1f5fe,stroke:#333
style E fill:#c8e6c9,stroke:#333
Beyond nucleotide metabolism, TYMP has other biological activities:
- Angiogenesis — Originally identified as PD-ECGF, promotes endothelial cell growth
- Tumor biology — Highly expressed in many cancers, associated with angiogenesis
- Immune modulation — Has chemotactic properties
- Inflammation — Expression regulated in inflammatory conditions
- Cytoplasm — Primary location, where enzymatic activity occurs
- Mitochondria — Some fraction associated with mitochondria for local nucleotide supply
- Extracellular — Can be secreted in some cell types
TYMP exhibits tissue-specific expression:
- Liver — Major site of nucleoside metabolism
- Brain — Neurons and glia, important for nucleotide homeostasis
- Intestine — Gastrointestinal epithelium
- Platelets — Contains PD-ECGF activity
- Heart — Mitochondrial-rich tissue
- Skeletal muscle — High mitochondrial content
- Kidney — Metabolic functions
MNGIE (OMIM #603041) is an autosomal recessive disorder caused by TYMP deficiency. It is characterized by:
Neurological Features:
- Progressive external ophthalmoplegia (PEO) — Eye movement limitation
- Leukoencephalopathy — White matter abnormalities on MRI
- Peripheral neuropathy — Sensorimotor deficits
- Cerebellar ataxia — Coordination problems
- Cognitive impairment — Variable severity
Gastrointestinal Features:
- Severe gastrointestinal dysmotility — Pseudo-obstruction
- Nausea, vomiting — Early symptoms
- Diarrhea or constipation — Variable
- Weight loss, failure to thrive — Due to malabsorption
Systemic Features:
- Hearing loss — Sensorineural
- Endocrine abnormalities — Variable
- Cachexia — Severe wasting
Pathogenesis:
- Accumulation of thymidine in blood and tissues
- Mitochondrial dNTP pool imbalance
- mtDNA depletion (typically 20-30% of normal)
- Progressive mtDNA loss leads to mitochondrial dysfunction
flowchart TD
A["TYMP Mutations<br/>Loss of Function"] --> B["Thymidine<br/>Accumulation"]
B --> C["Mitochondrial dNTP<br/>Pool Imbalance"]
C --> D["mtDNA<br/>Depletion"]
D --> E["Mitochondrial<br/>Dysfunction"]
E --> E1["PEO"]
E --> E2["Gastrointestinal<br/>Dysmotility"]
E --> E3["Leukoencephalopathy"]
E --> E4["Peripheral<br/>Neuropathy"]
E1 --> F["MNGIE<br/>Phenotype"]
E2 --> F
E3 --> F
E4 --> F
style A fill:#ffcdd2,stroke:#333
style F fill:#ffcdd2,stroke:#333
TYMP deficiency is classified as MTDPS type 1 (MTDPS1), one of several genetic forms of mtDNA depletion. The severity depends on residual enzyme activity:
- Severe childhood onset — Complete loss of function
- Late-onset — Partial enzyme activity allows later presentation
- Variable muscle involvement — Some patients have prominent myopathy
TYMP is frequently overexpressed in cancers:
- Angiogenesis — Promotes tumor vascularization
- Metastasis — Associated with invasive phenotype
- Prognosis — High expression often correlates with poor outcomes
- Therapeutic target — Some anticancer drugs target TYMP
- Inflammatory bowel disease — Altered expression
- Wound healing — Role in angiogenesis
- Atherosclerosis — May affect vascular remodeling
¶ Diagnosis and Testing
- Plasma thymidine — Markedly elevated in MNGIE
- Urine thymidine — Increased excretion
- Serum/plasma lactate — Often elevated
- CSF analysis — May show elevated lactate, protein
- Sequence analysis — Identifies TYMP pathogenic variants
- Targeted panels — Mitochondrial disease gene panels
- Whole exome sequencing — For suspected MNGIE
- Brain MRI — White matter changes (leukoencephalopathy)
- Abdominal imaging — Gastrointestinal involvement
- Allogeneic stem cell transplantation — Can reduce thymidine levels
- Liver transplantation — Provides enzyme source
- Supportive care — Nutritional support, physical therapy
- Monitoring — Regular assessment of progression
- Enzyme replacement — Recombinant TP therapy
- Gene therapy — Viral vector delivery of TYMP
- Small molecule approaches — Nucleoside analogs
- MTDPS-specific treatments under development
Recent advances in gene therapy offer new hope for TYMP deficiency:
- AAV vectors — Engineered AAV variants can cross the blood-brain barrier
- CRISPR-based approaches — Gene editing to correct pathogenic variants
- mRNA delivery — Direct delivery of functional TYMP mRNA
- Combination strategies — Gene therapy with enzyme replacement
Long-term management of MNGIE requires comprehensive care:
- Multidisciplinary care — Neurology, gastroenterology, genetics
- Monitoring biomarkers — Regular plasma thymidine measurements
- Nutritional support — Enteral feeding when needed
- Physical therapy — Maintain function and prevent complications
- Tymp knockout mice — Show thymidine accumulation and some mitochondrial dysfunction
- Zebrafish models — Demonstrate developmental effects
- Cell models — Patient-derived cells show mtDNA depletion
Key questions remain:
- Genotype-phenotype correlation — Why do different mutations cause different severity?
- Thymidine toxicity mechanisms — Exact pathway to tissue damage
- Therapeutic window — Best timing for intervention
- Biomarkers — For disease monitoring
¶ TyMP Structure and Catalytic Mechanism
Thymidine phosphorylase (TYMP) is a homodimeric enzyme with distinctive structural features:
Subunit Structure:
- Each subunit ~50 kDa
- Contains a large substrate binding pocket
- Dimeric arrangement is essential for activity
Active Site:
- Phosphate binding site
- Thymidine recognition region
- Catalytic residues for phosphorolysis
TYMP catalyzes the reversible phosphorolysis of thymidine:
Thymidine + phosphate ↔ Thymine + 2-deoxyribose-1-phosphate
Reaction Mechanism:
- Phosphate attacks C1' of deoxyribose
- Cleavage of glycosidic bond
- Thymine and 2-deoxyribose-1-phosphate released
- Equilibrium favors thymidine degradation
Substrate Specificity:
- Prefers thymidine as substrate
- Can act on other pyrimidine nucleosides
- Lower activity on deoxyuridine
¶ dNTP Pool Maintenance
TYMP plays a critical role in mitochondrial dNTP homeostasis:
Mitochondrial-Specific Requirements:
- Mitochondria have separate dNTP pools
- Mitochondrial dNTP synthesis differs from nuclear
-TK2 and TYMP are essential for mtDNA maintenance
Nucleotide Salvage Pathway:
- PYrimidine salvage recycles nucleosides
- TYMP processes thymidine from degradation
- Maintains balanced nucleotide pools
Proper nucleotide pools are essential for mtDNA replication:
Replication Requirements:
- dNTPs must be available for replication forks
- Leading and lagging strand synthesis
- Continuous nucleotide supply needed
Repair Functions:
- Mitochondria have base excision repair
- Nucleotide availability affects repair capacity
- TYMP deficiency impairs repair
flowchart TD
A["TYMP Activity"] --> B["Pyrimidine<br/>Salvage"]
B --> C["Mitochondrial dNTP<br/>Pool"]
C --> D["mtDNA<br/>Replication"]
C --> E["mtDNA<br/>Repair"]
D --> F["Mitochondrial<br/>Function"]
E --> F
style A fill:#e1f5fe,stroke:#333
style F fill:#c8e6c9,stroke:#333
MNGIE presents with progressive neurological involvement:
Ophthalmoplegia:
- Progressive external ophthalmoplegia (PEO)
- Ptosis (drooping eyelids)
- Eye movement limitation
Central Nervous System:
- Leukoencephalopathy on MRI
- Cerebellar ataxia
- Cognitive impairment (variable)
- Peripheral neuropathy
Peripheral Nervous System:
- Sensorimotor neuropathy
- Distal weakness
- Sensory loss
GI dysmotility is a hallmark of MNGIE:
Early Symptoms:
- Nausea and vomiting
- Early satiety
- Abdominal pain
Progressive Disease:
- Severe gastrointestinal dysmotility
- Pseudo-obstruction episodes
- Chronic diarrhea or constipation
Nutritional Consequences:
- Failure to thrive
- Weight loss and cachexia
- Requires nutritional support
Other Manifestations:
- Sensorineural hearing loss
- Endocrine abnormalities
- Short stature
- Cardiac involvement (rare)
TYMP deficiency leads to thymidine accumulation:
Metabolic Consequences:
- Plasma thymidine markedly elevated (50-150 μM)
- Tissue accumulation of thymidine
- Toxic effects on mitochondria
Mechanism of Toxicity:
- Thymidine interferes with mitochondrial function
- dNTP pool imbalance
- mtDNA depletion and deletions
MNGIE is characterized by mtDNA depletion:
Depletion Pattern:
- Typically 20-30% of normal mtDNA copy number
- Affects skeletal muscle most severely
- Variable across tissues
Molecular Mechanism:
- Inadequate nucleotides for replication
- Impaired mtDNA maintenance
- Progressive loss of mtDNA
The downstream effects include:
Bioenergetic Deficit:
- Reduced ATP production
- Complex I deficiency common
- Progressive respiratory failure
Morphological Changes:
- Ragged red fibers (muscle)
- Cytochrome c oxidase negative fibers
- Mitochondrial proliferation
Plasma Thymidine:
- Markedly elevated (>10 μM in MNGIE)
- Diagnostic specificity high
- Used for screening and monitoring
Other Biomarkers:
- Elevated urine thymidine
- Increased plasma deoxyuridine
- CSF thymidine (elevated)
TYMP Sequencing:
- Identifies pathogenic variants
- Confirms diagnosis
- Enables carrier testing
Common Mutations:
- Over 50 pathogenic variants known
- Missense mutations common
- Some founder mutations in populations
Brain MRI:
- White matter changes (leukoencephalopathy)
- Periventricular hyperintensities
- May progress over time
Muscle MRI:
- Fatty replacement patterns
- Helps guide muscle biopsy
Allogeneic Stem Cell Transplantation:
- Hematopoietic stem cell transplant
- Provides functional TYMP enzyme
- Reduces thymidine levels
- Risks include graft vs host disease
Liver Transplantation:
- Provides enzyme source
- Has been attempted in selected cases
- Limited by donor availability
Supportive Care:
- Nutritional support (enteral/parenteral)
- Physical therapy
- Management of complications
- Regular monitoring
Enzyme Replacement Therapy:
- Recombinant TP being developed
- Could reduce thymidine levels
- Requires regular administration
Gene Therapy:
- Viral vector delivery of TYMP
- May provide long-term correction
- In preclinical development
Small Molecule Approaches:
- Nucleoside analogs under study
- Could reduce thymidine toxicity
- Metabolite reduction strategies
flowchart TD
A["MNGIE<br/>Treatment Options"] --> B["Current<br/>Therapies"]
A --> C["Emerging<br/>Therapies"]
B --> B1["HSCT"]
B --> B2["Liver transplant"]
B --> B3["Supportive care"]
C --> C1["ERT"]
C --> C2["Gene therapy"]
C --> C3["Small molecules"]
B1 --> D["Reduced<br/>Thymidine"]
B2 --> D
B3 --> D
C1 --> D
C2 --> D
C3 --> D
style A fill:#e1f5fe,stroke:#333
style D fill:#c8e6c9,stroke:#333
Tymp Knockout Mice:
- Viable but show thymidine accumulation
- Mitochondrial dysfunction in tissues
- Phenotype milder than human disease
Transgenic Models:
- Tissue-specific deficiency
- Inducible models for study
- Phenotype modification studies
Preclinical Studies:
- Enzyme replacement efficacy
- Gene therapy delivery
- Small molecule testing
TYMP is frequently overexpressed in cancers:
Angiogenesis:
- Originally identified as PD-ECGF
- Promotes endothelial cell proliferation
- Associated with tumor vascularization
Prognostic Value:
- High expression often indicates poor prognosis
- Associated with metastasis
- Potential therapeutic target
TYMP Inhibitors:
- Being developed as anticancer agents
- Particularly relevant for certain tumors
- Combined with other therapies
¶ TYMP and Neuroinflammation
TYMP may play a role in neuroinflammation:
Microglial Activation:
- Expressed in microglia
- Modulates inflammatory responses
- May affect neurotoxicity
Therapeutic Implications:
- TYMP modulation in MS being explored
- Potential for neuroinflammatory diseases
- Cross-talk with other pathways
¶ TYMP and Mitochondrial Quality Control
TYMP affects mitochondrial dynamics:
Mitochondrial Fusion/Fission:
- dNTP levels affect mitochondrial dynamics
- May influence quality control
- Implications for neuronal survival
Autophagy:
- Mitophagy in mitochondrial quality control
- TYMP deficiency may affect clearance
- Linked to neurodegeneration
- Optimal therapy — What is the best treatment approach?
- Timing — When to intervene for maximum benefit?
- Biomarkers — What markers predict progression?
- Natural history — What determines disease course?
- Enzyme replacement trials planned
- Gene therapy approaches advancing
- Natural history studies ongoing